"Pharmaceutical headline Jun" retail pharmacy "one license quasi-camp" hepatitis B, hepatitis C infection.

(2020/08/04) in a nursing home! Lilly launched a phase III clinical trial of new coronary virus and antibodies; press the hoist to rise and rise: hepatitis B and C co-infection; what happens to those recovering from the new coronary critical illness? A follow-up note from 100 patients in 90 days by a front-line doctor... (Click on the title to get the original text) "Medicine 1st time" in the nursing home! Lilly's launch of Phase III clinical trials of new coronary virus and antibodies, Lilly announced that it had launched phase III BLAZE-2 trials in the United States, with the help of the U.S. government, mainly in people at high risk of infection and in poor health - long-term care facilities (usually nursing homes and assisted living communities) residents and staff, testing and antibody LY-CoV555 to prevent new coronary virus infection and treat COVID-19.
: It's unclear whether these antibody drugs will meet expectations.
the new coronary critically ill recovering from the new "eight o'clock health news"? First-line doctors 90 days 100 patients follow-up in the first phase of follow-up, Wuhan University Central South Hospital ICU director Peng Zhiyong found: 90% of critically ill patients still have impaired lung function; A further 10 per cent of patients had abnormalities in antibody testing, another 20 to 50 per cent had depression, and almost all follow-up patients had a greater or less sense of illness, making it difficult to fully return to normal life as before.
: 90% of critically ill patients have not yet fully recovered their lungs.
"E Pharmaceutical Manager" Heng Rui: five-year revenue growth first fell below 20% research and development investment growth of 25% August 1, Hengrui Pharmaceuticals announced the 2020 semi-annual report, from the total revenue and net profit to see Hengrui still maintain the domestic biopharmaceutical enterprises in the top position, but compared with the growth rate of the same period last year, the impact of the new crown epidemic is very prominent.
2020 half-yearly report shows that Hengrui Pharma's total revenue in the first half of the year was RMB11,309 million, up 12.79 percent from RMB10,026 million in the same period in the same period in 19 years;
: Research and development costs are making a reverse increase.
CDK 4/6 inhibitors introduced by The Pharmaceutical Missionary Pharmaceuticals for $170 million so popular? CDK 4/6 (cell cycle protein-dependent kinases 4 and 6) inhibitors are a rising star in cancer treatment in recent years.
as early as 2001, three scientists who had made significant contributions to the field of cell cycle regulation won the Nobel Prize in Physiology or Medicine.
, three CDK 4/6 inhibitors have been approved for market worldwide.
: More than 10 CDK 4/6 inhibitors are becoming clinical in China.
august 3rd, the era of "one-card quasi-camp" of retail pharmacies, the Chinese government's official website announced that it would further optimize the business environment through the reform of "control clothing".
focus on engineering construction, education, medical care, sports and other fields, focus on cleaning up the relevant departments and local market access in terms of enterprise qualifications, capital, share ratio, personnel, places and other unreasonable conditions.
headlines: Business start-ups are back to good.
10 traditional Chinese medicine is very strong! China Resources, Tai chi, Tongrentang... Nine brands selling more than 1 billion Chinese traditional medicine has been put on the agenda, in the face of traditional Chinese medicine medical insurance control fees and price reduction pressure, some enterprises will focus on the development of retail pharmacies.
meters in-network data show that in recent years, China's urban retail pharmacy terminal chinese medicine market has steadily increased in size, in 2019 its sales of more than 111.6 billion yuan, respiratory diseases, the leading drug use.
headline: a 100 billion retail market shuffle.
the U.S. Traditional Chinese Medicine Source: Hepatitis B, Hepatitis C co-infection recently NIH scientists in JCI published a study on hepatitis B, hepatitis C co-infection.
hepatitis B, hepatitis C co-infection is not very rare, has been clinically found to use high-efficiency hepatitis C drugs to cure hepatitis C will cause the reactivation of hepatitis B, the consequences are very serious.
: the rate of co-infection is not low.
.